Holzer et al., 1995 - Google Patents
Mediation by prostaglandins of the nitric oxide‐induced neurogenic vasodilatation in rat skinHolzer et al., 1995
View PDF- Document ID
- 838631211123095780
- Author
- Holzer P
- Jociĉ M
- Peskar B
- Publication year
- Publication venue
- British journal of pharmacology
External Links
Snippet
1 Intraplantar administration of the nitric oxide (NO) donor, sodium nitroprusside (SNP), induces hyperaemia in the rat paw skin, which is in part due to release of calcitonin gene‐ related peptide (CGRP) from afferent nerve fibres. The present study examined whether …
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 O=[N] 0 title abstract description 88
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Holzer et al. | Mediation by prostaglandins of the nitric oxide‐induced neurogenic vasodilatation in rat skin | |
| Trigo-Rocha et al. | Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs | |
| Iadecola et al. | Nitric oxide synthase inhibition and cerebrovascular regulation | |
| US5439938A (en) | Treatments for male sexual dysfunction | |
| Kastin et al. | Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease | |
| KR100517210B1 (en) | Infusion solution for pain, inflammation and spasm | |
| Messlinger et al. | Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat | |
| Holzer et al. | Cutaneous vasodilatation induced by nitric oxide-evoked stimulation of afferent nerves in the rat | |
| Holzer et al. | Nitric oxide‐dependent and‐independent hyperaemia due to calcitonin gene‐related peptide in the rat stomach | |
| Hellstrom et al. | Penile erection in the primate: induction with nitric-oxide donors | |
| Fox et al. | Neuroprotection by corticotropin releasing factor during hypoxia in rat brain. | |
| Sugita et al. | Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors | |
| Martinez-Piñeiro et al. | Cyclic guanosine monophosphate mediates penile erection in the rat | |
| Holzer et al. | Vascular bed‐dependent roles of the peptide CGRP and nitric oxide in acid‐evoked hyperaemia of the rat stomach. | |
| MCAULEY et al. | Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway | |
| Wachter et al. | Visceral vasodilatation and somatic vasoconstriction evoked by acid challenge of the rat gastric mucosa: diversity of mechanisms. | |
| Kihara et al. | Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide | |
| Talman et al. | Inhibition of nitric oxide synthesis extends cerebrovascular autoregulation during hypertension | |
| WO2021198216A1 (en) | New method to treat the hepatotoxicity induced by amanitins | |
| Kim et al. | The role of nitric oxide in vivo feline erection under hypoxia | |
| EP1383497B1 (en) | Carbonic anhydrase activators for enhancing learning and memory | |
| Takahashi et al. | Effect of intracavernous simultaneous injection of acetylcholine and vasoactive intestinal polypeptide on canine penile erection | |
| Melkumyants et al. | Nitric oxide does not mediate flow induced endothelium dependent arterial dilatation in the cat | |
| Király et al. | Peripheral mediators involved in gastric hyperemia to vagal activation by central TRH analog in rats | |
| US6043223A (en) | Enhanced opening of abnormal brain tissue capillaries |